Stem Cell Trials Against COVID-19

Stem Cell Trials Against COVID-19

Currently, ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) report a combined 29 trials exploring the potential of stem cells for treating COVID-19.
Interestingly, not all of the filed trials are being pursued. In recent weeks, five trials with Chinese Clinical Trial Register (“ChiCTR”) numbers and one trial from ClinicalTrials.gov (with a “National Clinical Trial”) number have been marked as “Cancelled by the Investigator.”
Four of the six withdrawn trials were submitted by the same Chinese company, Guangzhou Reborn Health Management Consultation Co., LTD. Thus, there are 23 active stem cell trials for COVID-19, the vast majority of which utilize MSCs. 16 of the ongoing trials have Chinese Clinical Trial Register (“ChiCTR”) numbers and 7 have National Clinical Trial (NCT) numbers.
When all trial types are considered, there are over 400 studies worldwide exploring approaches to diagnosing, treating or managing COVID-19. (https://bioinformant.com/product/coronavirus-covid-19-report/)

Clinicaltrials.gov (21. 3. 2020)